RECIST Criteria: Measuring Treatment Response in Ovarian Cancer Patients

RECIST criteria are the standardized rules doctors and radiologists use to measure whether your ovarian cancer is responding to treatment, staying stable, or progressing. 

If you’re undergoing chemotherapy for ovarian cancer or participating in a clinical trial, understanding how RECIST works can help you make sense of your scan results and have more informed conversations with your oncology team.

What is RECIST Criteria? RECIST Meaning

RECIST stands for Response Evaluation Criteria in Solid Tumors. Think of it as a universal measuring system — like using centimeters instead of inches — that ensures everyone is evaluating tumors the same way. The current version, RECIST 1.1, was published in 2009 and is used worldwide in clinical trials and cancer treatment monitoring.

Before RECIST, which is ​​based on the original World Health Organization (WHO) guidelines, different research groups and hospitals measured tumors differently, which made it nearly impossible to compare results across studies. Some measured tumors in two dimensions, others in one. Some counted ten lesions, others counted five. This inconsistency created confusion and made it harder to determine which treatments actually worked.

RECIST criteria radiology standards changed all that by creating one clear set of rules.

Why RECIST Matters for Ovarian Cancer Patients

Ovarian cancer often spreads throughout the abdomen, creating multiple tumor sites: on the ovaries, peritoneum (abdominal lining), omentum (fatty tissue in the abdomen), and lymph nodes. Tracking all of this disease can be complex, which is exactly why standardized measurement matters.

Here’s what RECIST criteria help determine:

• Whether your chemotherapy is working. After each treatment cycle, scans are compared to your baseline to see if tumors are shrinking, staying the same, or growing.
• If you’re eligible for surgery. For patients receiving neoadjuvant chemotherapy (chemo given before surgery to shrink tumors), RECIST measurements help doctors decide when you’ve responded enough for optimal debulking surgery.
• Your status in clinical trials. If you’re enrolled in a trial, RECIST is almost certainly being used to measure your response. According to the official RECIST 1.1 guidelines, objective response rates are critical endpoints that help determine whether new treatments should move forward in development.

How RECIST Criteria Work: The Basics

The RECIST system divides your cancer into different categories based on which tumors can be accurately measured and which ones can’t. Your baseline scan, usually a CT scan done before treatment starts, establishes the starting point that all future scans will be compared against.

Target Lesions: What Gets Measured

Your radiologist will identify up to five “target lesions”: the tumors that will be measured at every scan. These are typically the largest, most clearly visible tumors that represent your overall disease burden. The rules are specific: maximum of two lesions per organ, five total.

For ovarian cancer patients, target lesions might include:

• Ovarian masses
• Peritoneal implants (tumor deposits on the abdominal lining)
• Enlarged lymph nodes (must be at least 15mm in short axis)
• Liver metastases
• Omental disease (tumors in the fatty tissue of the abdomen)

Each target lesion gets measured in one dimension, the longest diameter. All these measurements are added together to create your “sum of diameters.” This baseline number becomes your reference point.

Non-Target Lesions: What Gets Noted

Not everything gets measured precisely. Smaller tumors, ascites (fluid buildup in the abdomen), pleural effusions (fluid around the lungs), and very tiny peritoneal implants are recorded as “non-target” lesions. These are tracked more generally as present, absent, or clearly worse.

For ovarian cancer, this is particularly relevant because peritoneal carcinomatosis — the spread of cancer throughout the abdominal lining — often involves countless tiny deposits that can’t all be individually measured.

The Four Response Categories

After each scan, your overall response falls into one of four categories:

Complete Response (CR): All target lesions have disappeared. Any lymph nodes must shrink to less than 10mm. This is rare in advanced ovarian cancer but can happen, particularly after aggressive treatment.

Partial Response (PR): Your sum of diameters has decreased by at least 30% compared to baseline. This represents significant tumor shrinkage and is generally what oncologists hope to see with effective chemotherapy.

Stable Disease (SD): Your tumors haven’t shrunk enough to qualify as PR (less than 30% decrease) but haven’t grown enough to be considered progression (less than 20% increase). Stable disease isn’t necessarily bad; it means treatment is controlling your cancer.

Progressive Disease (PD): Your sum of diameters has increased by at least 20% AND at least 5mm compared to the smallest measurement during treatment. Or, new lesions have appeared. This typically means it’s time to change treatment strategies.

What Your Doctor Sees on the Scan Report

When your radiologist reviews your CT or MRI, they’re following very specific RECIST imaging protocols. According to RECIST 1.1 guidelines, scans should be performed with consistent technique (same contrast timing, same slice thickness, same imaging protocol) to ensure measurements are comparable.

For example, if a liver metastasis measured 35mm at baseline and now measures 20mm, that’s a 15mm decrease. If your other target lesions also decreased proportionally, you might achieve a partial response.

But it’s not always straightforward. Lymph nodes are measured differently (by short axis, not long axis). Lesions that break apart or merge together need special consideration. And sometimes what looks like a “new” lesion is actually just better visible due to technique differences.

This is why having the same radiologist, or at least the same imaging center, review your scans can improve consistency.

RECIST and CA-125: How They Work Together

Many ovarian cancer patients wonder how RECIST criteria relate to CA-125 blood tests. They’re complementary but different.

CA-125 measures a protein in your blood that’s often elevated with ovarian cancer. RECIST measures the actual physical tumor burden on imaging. Both are valuable, but they don’t always move in sync. Meaning: you might have a rising CA-125 with stable RECIST measurements, or vice versa. 

For first-line ovarian cancer clinical trials, the Gynecologic Cancer InterGroup (GCIG) has developed criteria that combine both CA-125 and RECIST to define progression.

When RECIST Has Limitations in Ovarian Cancer

RECIST criteria work well for many cancers, but ovarian cancer presents unique challenges.

Small volume peritoneal disease is hard to measure. According to imaging research, CT scans struggle to detect peritoneal implants smaller than 5mm. Yet these tiny deposits can still represent active disease. (Learn more: Can a CT Scan Detect Ovarian Cancer?) 

Ascites and pleural effusions aren’t precisely measured. These are common in ovarian cancer but are classified as non-target lesions. Worsening fluid can indicate progression, but RECIST doesn’t quantify it precisely.

Borderline tumors and low-grade serous ovarian cancer may not change much. These subtypes tend to grow slowly. For patients with LGSOC, having tumors that remain stable over many months can represent effective disease control, even though the tumors haven’t dramatically shrunk.

Response after neoadjuvant chemo can be complex. If you’ve had three cycles of chemo and your tumors have shrunk significantly, deciding the optimal timing for interval debulking surgery involves more than just RECIST. It requires clinical judgment about whether the surgeon can remove all visible disease.

RECIST in Clinical Trials: What Participants Should Know

If you’re considering or enrolled in an ovarian cancer clinical trial, RECIST will likely be central to how your response is evaluated. According to the RECIST 1.1 guidelines, phase II trials (the studies testing whether a new drug works) often use objective response rate as their primary endpoint.

This means the percentage of patients who achieve CR or PR determines whether a drug advances to larger trials.

For phase III randomized trials, progression-free survival (PFS) is often the main endpoint. This measures how long you live without your disease progressing according to RECIST criteria. Understanding this helps you interpret trial results and decide if a study might be right for you.

Some trials are now incorporating more advanced imaging like PET/CT scans alongside standard RECIST measurements. PET scans use a special radioactive sugar (called FDG) that cancer cells absorb more readily than normal cells. 

Research shows that changes in how much sugar the tumor absorbs can be detected earlier than changes in tumor size on regular CT scans. This means PET/CT might identify patients whose cancer isn’t responding to treatment sooner than traditional imaging alone.

Questions to Ask Your Doctor

Understanding RECIST empowers you to have better conversations about ovarian cancer treatment. Consider asking:

• “What were my baseline measurements, and what are they now?”
• “Am I meeting criteria for partial response, or is my disease stable?”
• “Are there any non-target lesions that concern you, even if my target lesions look stable?”
• “If I have stable disease, does that mean the treatment isn’t working, or is that actually a good outcome for my cancer type?”

For patients with borderline ovarian tumors or LGSOC, stable disease can be a meaningful benefit, as these cancers don’t always shrink dramatically with chemotherapy.

RECIST Criteria Radiology: The Bottom Line

RECIST criteria provide the framework for measuring how your ovarian cancer responds to treatment. While the system has limitations, particularly with the small peritoneal deposits and fluid accumulations common in ovarian cancer, it remains the gold standard that doctors worldwide use to assess whether treatment is working.

Understanding what RECIST means helps you interpret your scan results with clarity. When your doctor says you have a “partial response,” you’ll know your tumors have shrunk by at least 30%. When they mention “stable disease,” you’ll understand that your cancer is being controlled, even if it hasn’t dramatically shrunk. 

The more you know about how your disease is being monitored, the better equipped you are to participate in your own care and make decisions that align with your goals.